NanoViricides, Inc. — Form 10-K Summary
Reporting period: Fiscal year ended June 30, 2021. Although the request metadata refers to “2020 Q4,” this filing reports fiscal 2021 annual results, with comparisons to fiscal 2020.
Business context
NanoViricides is a development-stage antiviral drug company with no commercial products, customers, or revenue. Its lead programs were the COVID-19 candidates NV-CoV-2 and NV-CoV-2-R; shingles candidate NV-HHV-101 was also advanced but put on hold while resources were focused on COVID-19. The company owns a cGMP-capable manufacturing facility and relies on TheraCour Pharma, a related party, for licensed technology and development work.
Financial results and liquidity
| Metric | FY2021 | FY2020 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $6.11 million | $4.70 million |
| General and administrative expense | $2.63 million | $3.30 million |
| Total operating expenses / operating loss | $8.74 million | $8.00 million |
| Net loss | $8.82 million | $13.45 million |
| Basic and diluted loss per share | $0.81 | $2.39 |
| Net cash used in operating activities | $8.21 million | $6.67 million |
| Cash and cash equivalents at year-end | $20.52 million | $13.71 million |
| Working capital | $20.47 million | $11.83 million |
| Total assets | $30.26 million | $23.91 million |
| Total current liabilities | $0.35 million | $2.16 million |
The company reported no long-term liabilities. Current liabilities included a $95,306 insurance-financing loan; the related-party mortgage loan was repaid in December 2020. Operating margin is not meaningful because the company had no revenue. The audited financial statements received an unqualified opinion; the auditor did not express an opinion on internal-control effectiveness.
Material changes versus the prior year
- R&D expense rose $1.42 million, principally due to COVID-19 development, lab supplies, employee compensation, and pre-IND work. COVID-19 accounted for $5.56 million of FY2021 R&D; HerpeCide accounted for $0.55 million.
- G&A expense fell $0.67 million, mainly from lower legal, professional, and office-salary costs.
- Net loss narrowed by $4.62 million, largely because FY2020 included a $5.85 million derivative fair-value loss and a $0.14 million related-party preferred-stock exchange loss. FY2021 R&D spending increased.
- Cash increased by $6.81 million. Financing provided $15.26 million, including approximately $10.4 million from a July 2020 stock offering and $6.1 million net from an ATM share sale; operating and investing activities used cash.
- Common shares outstanding increased from 9.08 million to 11.52 million, primarily reflecting equity financing. The company has an ATM agreement authorizing up to $50 million in aggregate sales, subject to its terms and future company instructions.
Outlook, risks, and unusual items
- Management estimated cash resources would fund planned operations through October 2022 and expected approximately $15.2 million in expenditures for the following year, including clinical and R&D spending. It estimated a further approximately $13 million would be needed for subsequent development plans. These are estimates, not commitments or assurances.
- Management’s stated priorities were to prepare regulatory filings and advance NV-CoV-2 and NV-CoV-2-R into initial human studies. It also identified further development of NV-HHV-101 as a later priority. The filing provides no assured clinical-trial or approval timeline and says it cannot reliably project when a candidate might be approved.
- The filing describes promising preclinical and animal-model results, but the candidates had not been tested in humans. Preclinical findings do not establish human safety or efficacy. The filing says GLP safety/toxicology reports were received in August 2021, while another section describes reports as draft or still in quality review; the status is not consistent throughout the text.
- On September 9, 2021, after fiscal year-end, the company entered an exclusive coronavirus-field license with TheraCour. Terms include milestone payments, Series A preferred-stock issuances, and a 15% royalty on net sales. TheraCour retains exclusive development and manufacturing rights under the agreement. The relationship is a significant related-party dependency; the filing identifies Dr. Anil Diwan as controlling approximately 90% of TheraCour and recusing himself from certain matters.
- Management identified a material weakness in financial reporting controls, citing inadequate and untimely review of the period-end close and filings and insufficient personnel and resources. It said remediation efforts had begun, but the weakness was not remediated as of June 30, 2021.
- Key risks include continued operating losses and future financing needs, clinical and regulatory failure or delay, dependence on external CROs and TheraCour, limited staffing, competitive pressure, potential dilution from equity issuance, and uncertainty about patent protection. The company reported no legal proceedings believed to have a material adverse effect.
Most important facts for investors to verify
- Current regulatory status, IND submission or acceptance, and actual timing and design of human trials for both COVID-19 candidates.
- Whether final GLP reports support the stated safety conclusions, and whether any further studies or regulatory requests are required.
- Cash burn and runway against management’s forecasts, including the expected funding gap for later-stage trials and the potential use of the ATM facility.
- Full related-party license economics, milestone obligations, manufacturing arrangements, and governance safeguards involving TheraCour.
- Progress and independent validation of clinical manufacturing readiness, capacity, quality controls, and required regulatory approvals.
- Remediation and independent assessment of the disclosed material weakness in financial reporting controls.